Merisone and associated names

  • Procedure started
  • Under evaluation
  • CHMP opinion
  • European Commission final decision
Current status
European Commission final decision

Overview

On 23 April 2015, the European Medicines Agency completed two arbitration procedures following a disagreement among Member States of the European Union (EU) regarding the authorisation of the medicines Merisone and Myoson (tolperisone). The Agency's Committee for Medicinal Products for Human Use (CHMP) concluded that the benefits of Merisone and Myoson outweigh their risks, and the marketing authorisation granted in Hungary can be recognised in other Member States of the EU.

Key facts

About this medicine
Approved name
Merisone and associated names
International non-proprietary name (INN) or common name
tolperisone
Class
-
About this procedure
Current status
European Commission final decision
Reference number
EMEA/H/A-29/1411
Type
Article 29(4) referrals

This type of referral is triggered when there is a disagreement between Member States regarding a marketing authorisation application being evaluated in a mutual-recognition or decentralised procedure, on the grounds of a potential serious risk to public health.

Key dates and outcomes
CHMP opinion date
23/04/2015
EC decision date
25/06/2015

All documents

Opinion provided by Committee for Medicinal Products for Human Use

  • List item

    Questions and answers on Merisone and Myoson (tolperisone, 50 and 150 mg tablets) (PDF/75.54 KB)


    First published: 24/04/2015
    Last updated: 28/07/2015
    EMA/252261/2015

  • List item

    Merisone Article-29(4) referral - Annex III (PDF/20.32 KB)


    First published: 24/04/2015
    Last updated: 28/07/2015
    EMEA/H/A-29/1411, EMEA/H/A-29/1412

  • European Commission final decision

  • List item

    Merisone Article-29(4) referral - Annex I (PDF/35.88 KB)


    First published: 28/07/2015
    Last updated: 28/07/2015

  • List item

    Merisone Article-29(4) referral - Annex II (PDF/48.4 KB)


    First published: 28/07/2015
    Last updated: 28/07/2015

  • List item

    Merisone and associated names Article 29(4) referral - Assessment report (PDF/168.18 KB)

    Adopted

    First published: 28/07/2015
    Last updated: 28/07/2015
    EMA/445102/2015

  • Description of documents published

    Please note that some of the listed documents apply only to certain procedures.

    • Overview - lay-language summary of the stage of the procedure
    • Notification – a letter from a Member State, the European Commission or the marketing authorisation holder requesting the initiation of the procedure
    • Scientific background – further background information from the triggering Member State on the issues leading to the initiation of the procedure (if applicable)
    • List of questions – questions agreed by the Committee requesting further information from the marketing authorisation holder(s) / applicant(s) to evaluate the issues identified
    • Timetable for the procedure – agreed timeframe to respond to the list of questions, to assess the issues and to adopt a conclusion
    • List of medicines concerned by the procedure – medicine(s) / active substance(s) concerned, and marketing authorisation holder(s) / applicant(s)
    • List of questions to be addressed by the stakeholders – call for data to be submitted by stakeholders (e.g. healthcare professionals, patient organisations, individual patients) (if applicable)
    • Stakeholder submission form – form to be used by stakeholders to submit data (if applicable)
    • Scientific conclusions – scientific conclusions of the PRAC and/or CHMP and/or CMDh
    • Assessment report – PRAC or CHMP assessment and conclusions on the issues investigated, including divergent positions (if applicable)
    • Divergent positions – divergent positions of the CHMP or CMDh members for pharmacovigilance procedures (if applicable)
    • Changes to the summary of product characteristics, labelling and package leaflet (amended sections or fully revised version) (if applicable)
    • Condition(s) to the marketing authorisation(s) – condition(s) for the safe and effective use of the medicine(s) (if applicable)
    • Condition for lifting the suspension – condition to be fulfilled for the suspension of the marketing authorisation(s) to be lifted (if applicable)
    • Timetable for implementation of CMDh position – agreed timeframe to submit and finalise the variation(s) implementing the outcome of the procedure (if applicable)

    Note that older documents may have different titles.

    How useful was this page?

    Add your rating